- Home
- OLP vs KROS Comparison
OLP vs KROS Comparison
Compare OLP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- KROS
- Stock Information
- Founded
- OLP 1982
- KROS 2015
- Country
- OLP United States
- KROS United States
- Employees
- OLP N/A
- KROS 163
- Industry
- OLP Real Estate Investment Trusts
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- OLP Real Estate
- KROS Health Care
- Exchange
- OLP Nasdaq
- KROS Nasdaq
- Market Cap
- OLP 569.9M
- KROS 558.9M
- IPO Year
- OLP N/A
- KROS 2020
- Fundamental
- Price
- OLP $23.80
- KROS $13.35
- Analyst Decision
- OLP Strong Buy
- KROS Buy
- Analyst Count
- OLP 1
- KROS 13
- Target Price
- OLP $28.00
- KROS $20.63
- AVG Volume (30 Days)
- OLP 70.5K
- KROS 620.1K
- Earning Date
- OLP 08-05-2025
- KROS 08-06-2025
- Dividend Yield
- OLP 7.59%
- KROS N/A
- EPS Growth
- OLP N/A
- KROS N/A
- EPS
- OLP 1.35
- KROS 0.11
- Revenue
- OLP $92,152,000.00
- KROS $214,713,000.00
- Revenue This Year
- OLP $11.87
- KROS $5,006.76
- Revenue Next Year
- OLP $4.72
- KROS N/A
- P/E Ratio
- OLP $17.59
- KROS $123.16
- Revenue Growth
- OLP 3.31
- KROS 91657.70
- 52 Week Low
- OLP $22.32
- KROS $9.12
- 52 Week High
- OLP $30.45
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- OLP 39.64
- KROS 43.06
- Support Level
- OLP $23.67
- KROS $13.41
- Resistance Level
- OLP $25.51
- KROS $13.99
- Average True Range (ATR)
- OLP 0.53
- KROS 0.44
- MACD
- OLP -0.15
- KROS -0.07
- Stochastic Oscillator
- OLP 6.28
- KROS 9.84
About OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.